Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

Abou-Alfa Ghassan K.; Lewis Lionel D.; LoRusso Patricia; Maitland Michael; Chandra Priya; Cheeti Sravanthi; Colburn Dawn; Williams Sarah; Simmons Brian; Graham Richard A.

首页> 外文期刊>Cancer chemotherapy and pharmacology. >Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

【24h】

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

机译：先进实体恶性肿瘤和肝障碍患者Vismodegib的药代动力学和安全性

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Vismodegib is a Hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma. Currently, the pharmacokinetics (PK) and safety of vismodegib in patients with hepatic dysfunction are unknown and are the objective of this study.

机译：Vismodegib是一种被批准用于治疗晚期基底细胞癌的刺猬途径抑制剂。目前，vismodegib在肝功能不全患者中的药代动力学（PK）和安全性尚不清楚，这是本研究的目标。

著录项

来源
《Cancer chemotherapy and pharmacology.》 |2017年第1期|共8页
作者
Abou-Alfa Ghassan K.; Lewis Lionel D.; LoRusso Patricia; Maitland Michael; Chandra Priya; Cheeti Sravanthi; Colburn Dawn; Williams Sarah; Simmons Brian; Graham Richard A.;
展开▼
作者单位

Mem Sloan Kettering Canc Ctr 300 East 66th St New York NY 10065 USA;

Norris Cotton Canc Ctr Hanover NH USA;

Barbara Ann Karmanos Canc Inst Detroit MI USA;

Univ Chicago Med Ctr Chicago IL 60637 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

Roche Prod Ltd Welwyn Garden City Herts England;

Genentech Inc San Francisco CA 94080 USA;

Genentech Inc San Francisco CA 94080 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
Vismodegib; Hepatic; Impairment; Safety; Pharmacokinetics;

机译：Vismodegib;肝脏;损伤;安全;药代动力学;

相似文献

外文文献
中文文献
专利

1. Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer [J] . WU Jian-yu, WU Xiao-nan, DING Li, 中华医学杂志：英文版 . 2010,第007期
2. Phase I safety and pharmacokinetic study of bevacizumab in Chinese patients with advanced cancer [J] . WU Jian-yu, WU Xiao-nan, DING Li, 中华医学杂志（英文版） . 2010,第007期
3. Pharmacokinetic characteristics of vincristine sulfate liposomes in patients with advanced solid tumors [J] . Zhao YAN, Zhong-ling ZHU, Zheng-zi QIAN, 中国药理学报：英文版 . 2012,第006期
4. Pharmacokinetics of panaxatrol disuccinate sodium, a novel anti-cancer drug from Panax notoginseng, in healthy volunteers and patients with advanced solid tumors [J] . Zhao MAN, Zhong-ling ZHU, Hua-qing WANG, 中国药理学报：英文版 . 2010,第011期
5. Pharmacokinetics of panaxatrol disuccinate sodium, a novel anti-cancer drug from Panax notoginseng, in healthy volunteers and patients with advanced solid tumors [J] . Zhao YAN, Zhong-ling ZHU, Hua-qing WANG, 中国药理学报：英文版 . 2010,第011期
6. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment [J] . Abou-Alfa Ghassan K., Lewis Lionel D., LoRusso Patricia, Cancer chemotherapy and pharmacology. . 2017,第1期

机译：先进实体恶性肿瘤和肝损伤患者Vismodegib的药代动力学和安全性
7. Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment [J] . Grechko Nikolay, Skarbova Viera, Tomaszewska-Kiecana Monika, Cancer chemotherapy and pharmacology. . 2021,第2期

机译：高级实体肿瘤和肝损伤患者Rucaparib的药代动力学和安全性
8. Open‐label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment [J] . Saif Muhammad Wasif, Rosen Lee, Rudek Michelle A., British Journal of Clinical Pharmacology . 2019,第6期

机译：开放标签研究评估先进实体肿瘤和肝损伤患者患者的三氟叶醛/ TIPIRACIL安全性，耐受性和药代动力学
9. MATURE MYSTERIES: "OLD AGE AIN'T NO PLACE FOR SISSIES" MANAGING OSTEOARTHRITIS IN PATIENTS WITH RENAL OR HEPATIC IMPAIRMENT [C] . Gregory F. Grauer Annual Meeting of the American Animal Hospital Association . 2008

机译：成熟的谜团：“旧时代不是啜饮的地方”管理肾病或肝病患者骨关节炎
10. Design evaluation for pharmacokinetic studies in patients with renal impairment [D] . Liu, Jin 2007

机译：肾功能不全患者药代动力学研究的设计评估
11. Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment [O] . Ghassan K. Abou-Alfa, Lionel D. Lewis, Patricia LoRusso, -1

机译：vismodegib在晚期实体恶性肿瘤和肝功能不全患者中的药代动力学和安全性
12. A Phase 1, open-label, multicentre study to compare the capsule and tablet formulations of AZD5363 and explore the effect of food on the pharmacokinetic exposure, safety and tolerability of AZD5363 in patients with advanced solid malignancies: OAK [O] . Emma Dean, Udai Banerji, Jan H. M. Schellens, 2018

机译：1期，开放标签，多期式研究，以比较AZD5363的胶囊和片剂配方，探讨食物对先进实体恶性肿瘤患者AZD5363的药代动力学暴露，安全性和耐受性：橡木
13. Guidance for Industry. Pharmacokinetics in Patients with Impaired Renal Function211 Study Design, Data Analysis, and Impact on Dosing and Labeling [R] . 1998

机译：工业指南。肾功能受损患者的药代动力学211研究设计，数据分析以及对剂量和标记的影响

Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment

摘要

著录项

相似文献

相关主题

期刊订阅